Archean Chemical invests Rs 170 crore in subsidiary via rights issue
Archean Chemical Industries Limited has approved an investment of up to Rs 170 crore in its wholly owned subsidiary, Acume Chemicals Private Limited, through a rights issue subscription approved by the Board on May 11, 2026. The investment aims to strengthen the subsidiary's capital base, support expansion, improve capacity utilisation, and reduce external borrowings. Acume Chemicals, incorporated in 2021 and operating in the Bromine Derivatives business, reported total assets of Rs 28,649.78 lakh and revenue of Rs 8,111.53 lakh as of March 31, 2026. The subscription will be completed in one or more tranches within a month of the rights offer, maintaining 100% ownership.
*this image is generated using AI for illustrative purposes only.
Archean Chemical Industries Limited has commenced the subscription process to invest up to Rs 170 crore in its wholly owned subsidiary, Acume Chemicals Private Limited, through a rights issue. The Board of Directors approved this investment on May 11, 2026, to strengthen the capital base of the subsidiary and support its future business expansion. The funds will be utilized to improve capacity utilisation, enhance product mix, and reduce external borrowings, thereby strengthening the balance sheet of Acume Chemicals.
The company will subscribe to equity shares of Acume Chemicals in one or more tranches, with the total investment not exceeding Rs 170,00,00,000. The subscription is proposed to be completed within one month from the date of the rights offer. The transaction constitutes a related party transaction as Acume Chemicals is a wholly owned subsidiary, and the subscription is being undertaken on a rights basis proportionate to the company's existing shareholding. The consideration for the acquisition will be in cash, with shares subscribed at a face value of Rs 10 per share.
Acume Chemicals Private Limited, incorporated on November 18, 2021, operates in the chemical industry, specifically in the Bromine Derivatives business. As of March 31, 2026, the subsidiary reported total assets of Rs 28,649.78 lakh and revenue from operations of Rs 8,111.53 lakh. The company holds 100% of the equity share capital of Acume Chemicals and will maintain this ownership level post-subscription. No separate governmental or regulatory approvals are presently required for the investment, which will be conducted in accordance with the Companies Act, 2013.
Financial Performance of Acume Chemicals
The subsidiary has demonstrated significant growth in turnover over the past three years. The following table details the financial performance of Acume Chemicals:
| Years | Turn over (Rs in Lakhs) |
|---|---|
| 2024-25 | 8111.53 |
| 2023-24 | 2717.86 |
| 2022-23 | 51.44 |
Key Details of the Investment
| Particular | Details |
|---|---|
| Target Entity | Acume Chemicals Private Limited |
| Investment Amount | Up to Rs 170 crore |
| Purpose | Capital base strengthening, expansion, debt reduction |
| Shareholding Post-Investment | 100% |
| Completion Timeline | Within one month of rights offer |
Historical Stock Returns for Archean Chemical Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.90% | +0.07% | -13.97% | +4.52% | -14.44% | +16.83% |
What specific capacity expansion projects does Acume Chemicals plan to undertake with the Rs 170 crore infusion?
How will the reduction in external borrowings impact Acume Chemicals' interest costs and overall profitability in the next fiscal year?
Given the three-fold revenue increase in 2024-25, what are the projected growth rates for Acume Chemicals post-investment?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
